ClinicalTrials.gg
CompletedNCT00191451Updated Nov 20, 2009Results posted

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

A Phase 2 interventional study of Gemcitabine and Carboplatin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
23rd of 90
150 · median 68
Started
2004
with 9 others
Phase 2
65 of 95
none open now
Registered
22nd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 23rd largest by enrollment of the 90 interventional ones that give a count, is one of 10 that started in 2004, is one of 65 in phase 2, and was the 22nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cancer. How long the treatment will stop the growth of the cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of breast cancer
  2. Able to visit the doctor's office at least every 14 days during the actual treatment
  3. Able to care for yourself, even if you cannot work or participate in other normal activities
  4. Your blood results must be adequate for therapy.
  5. If you are a female of and test negative for pregnancy, use a reliable method of during and for three months following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Have received gemcitabine, paraplatin, or trastuzumab for your cancer.
  2. Be pregnant or breastfeeding
  3. Have cancer to the brain and has not been treated
  4. Have another active cancer besides breast cancer
  5. Have received stem cell or bone marrow transplant for hematologic (blood type) cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    HER2+

    Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.

    Drug: Gemcitabine · Drug: Carboplatin · Drug: Herceptin

  • Experimental
    HER2- (Taxane-)

    Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).

    Drug: Gemcitabine · Drug: Carboplatin

  • Experimental
    HER2- (Taxane+)

    Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).

    Drug: Gemcitabine · Drug: Carboplatin

Interventions

  • Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)

    Also known as: Gemzar

  • Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).

    Also known as: Paraplatin

  • Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion). Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion).

06

What researchers measure

Primary outcomes

  1. Overall Tumor Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to disease progression/recurrence (up to 3.5 years)

Secondary outcomes

  1. Duration of Response

    Among tumor responders, the duration of tumor response is measured from the date of response (complete response \[CR\] or partial response \[PR\]) until the first date of documented progression or death from any cause. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.

    Time frame: date of response (CR or PR) until the first date of documented progression or death from any cause (up to 3.5 years)

  2. Number of Patients Who Experienced Alopecia

    Time frame: Baseline to 3.5 years

  3. Time to Disease Progression (TTP)

    If a patient is lost to follow-up, the patient will be censored as of the last date of contact. Patients who start a new treatment before they progress will be censored as of the date of start of the new treatment. If a patient died due to reason other than study disease, and patient has not progressed or received any new treatment, TTP is censored at the date of death.

    Time frame: randomization date to the earliest date of the first documented disease progression date or the date of death if the patient dies due to study disease (up to 3.5 years)

  4. Percentage of Patients With Overall Survival at 1 Year and 2 Years

    Kaplan-Meier estimates of overall survival (percentage of patients surviving) at 1 year and 2 years.

    Time frame: 1 Year, 2 Years

07

Results

Posted Nov 17, 2009

Participant flow

Participant flow — Overall Study
MilestoneHER2+HER2- (Taxane-)HER2- (Taxane+)
Started505149
Received at least one dose of study drug504847
Completed433735
Not completed71414
Withdrew: Withdrawal by subject235
Withdrew: Physician decision296
Withdrew: Sponsor decision100
Withdrew: Ineligible010
Withdrew: Reason not specified213

Outcome measures

PrimaryOverall Tumor Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to disease progression/recurrence (up to 3.5 years)
Reported as:
Number · participants
Overall Tumor Response
participantsHER2+HER2- (Taxane-)HER2- (Taxane+)
Complete Response (CR)601
Partial Response (PR)261315
Stable Disease (SD)122013
Progressive Disease (PD)41217
Not Evaluable (NE)221
SecondaryDuration of Response

Among tumor responders, the duration of tumor response is measured from the date of response (complete response \[CR\] or partial response \[PR\]) until the first date of documented progression or death from any cause. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.

Time frame:
date of response (CR or PR) until the first date of documented progression or death from any cause (up to 3.5 years)
Reported as:
Median · months
Duration of Response
monthsHER2+HER2- (Taxane-)HER2- (Taxane+)
Duration of Response6.9 (2.0 to 42.1)6.4 (3.5 to 29.7)5.6 (2.3 to 14.8)
SecondaryNumber of Patients Who Experienced Alopecia
Time frame:
Baseline to 3.5 years
Reported as:
Number · participants
Number of Patients Who Experienced Alopecia
participantsHER2+HER2- (Taxane-)HER2- (Taxane+)
Number of Patients Who Experienced Alopecia211716
SecondaryTime to Disease Progression (TTP)

If a patient is lost to follow-up, the patient will be censored as of the last date of contact. Patients who start a new treatment before they progress will be censored as of the date of start of the new treatment. If a patient died due to reason other than study disease, and patient has not progressed or received any new treatment, TTP is censored at the date of death.

Time frame:
randomization date to the earliest date of the first documented disease progression date or the date of death if the patient dies due to study disease (up to 3.5 years)
Reported as:
Median · months
Time to Disease Progression (TTP)
monthsHER2+HER2- (Taxane-)HER2- (Taxane+)
Time to Disease Progression (TTP)7.2 (6.0 to 9.0)5.6 (3.3 to 7.2)4.6 (1.8 to 9.0)
SecondaryPercentage of Patients With Overall Survival at 1 Year and 2 Years

Kaplan-Meier estimates of overall survival (percentage of patients surviving) at 1 year and 2 years.

Time frame:
1 Year, 2 Years
Reported as:
Number · percentage of participants
Percentage of Patients With Overall Survival at 1 Year and 2 Years
percentage of participantsHER2+HER2- (Taxane-)HER2- (Taxane+)
1 Year Overall Survival90.067.547.8
2 Year Overall Survival73.341.420.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HER2+—10/50 (20%)50/50 (100%)
HER2- (Taxane-)—11/48 (22.9%)48/48 (100%)
HER2- (Taxane+)—10/47 (21.3%)45/47 (95.7%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventHER2+HER2- (Taxane-)HER2- (Taxane+)
AnaemiaBlood and lymphatic system disorders0/504/482/47
DyspnoeaRespiratory, thoracic and mediastinal disorders1/504/482/47
NeutropeniaBlood and lymphatic system disorders0/502/481/47
ThrombocytopeniaBlood and lymphatic system disorders0/502/480/47
PyrexiaGeneral disorders0/502/480/47
Febrile neutropeniaBlood and lymphatic system disorders0/500/481/47
Intestinal obstructionGastrointestinal disorders0/500/481/47
NauseaGastrointestinal disorders1/500/481/47
OesophagitisGastrointestinal disorders0/500/481/47
Upper gastrointestinal haemorrhageGastrointestinal disorders0/500/481/47
Most frequent other events
Showing 10 of 89
Most frequent other events
EventHER2+HER2- (Taxane-)HER2- (Taxane+)
NeutropeniaBlood and lymphatic system disorders35/5037/4828/47
FatigueGeneral disorders37/5035/4830/47
NauseaGastrointestinal disorders27/5033/4822/47
AnaemiaBlood and lymphatic system disorders31/5024/4822/47
AlopeciaSkin and subcutaneous tissue disorders21/5017/4816/47
LeukopeniaBlood and lymphatic system disorders16/5020/4810/47
ConstipationGastrointestinal disorders19/5019/4814/47
VomitingGastrointestinal disorders13/5018/4812/47
ThrombocytopeniaBlood and lymphatic system disorders13/5017/4815/47
CoughRespiratory, thoracic and mediastinal disorders16/5011/4810/47

Baseline characteristics

Age Continuous
Age Continuous(years)HER2+HER2- (Taxane-)HER2- (Taxane+)Total
Mean56.1 ± 9.4555.7 ± 11.1754.8 ± 9.9255.55 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)HER2+HER2- (Taxane-)HER2- (Taxane+)Total
Female505149150
Male0000
Region of Enrollment
Region of Enrollment(participants)HER2+HER2- (Taxane-)HER2- (Taxane+)Total
United States505149150
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)HER2+HER2- (Taxane-)HER2- (Taxane+)Total
0 - Fully Active413632109
1 - Ambulatory, Restricted Strenuous Activity8141739
2 - Ambulatory, No Work Activities1102
Race/Ethnicity
Race/Ethnicity(participants)HER2+HER2- (Taxane-)HER2- (Taxane+)Total
Caucasian314236109
Black851124
Hispanic74112
Other4015
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46203, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Apr 2004
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 17, 2009
Last update
Nov 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191451
First posted
Sep 19, 2005
Start date
Apr 2004
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 17, 2009
Last update
Nov 20, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Carboplatin

Start the discussion